SAGE Therapeutics Inc (NASDAQ:SAGE) has received an average rating of “Buy” from the sixteen brokerages that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and eleven have issued a buy rating on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $175.75.
A number of brokerages have weighed in on SAGE. BidaskClub lowered SAGE Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday. JPMorgan Chase & Co. restated a “buy” rating on shares of SAGE Therapeutics in a research note on Wednesday, January 10th. Cowen restated a “buy” rating on shares of SAGE Therapeutics in a research note on Monday, December 11th. Stifel Nicolaus restated a “buy” rating and issued a $198.00 target price on shares of SAGE Therapeutics in a research note on Friday, December 8th. Finally, SunTrust Banks upped their price objective on SAGE Therapeutics to $178.00 and gave the stock a “positive” rating in a report on Friday, December 8th.
SAGE Therapeutics (NASDAQ:SAGE) opened at $159.34 on Tuesday. The firm has a market capitalization of $6,540.00, a PE ratio of -23.19 and a beta of 2.97. SAGE Therapeutics has a one year low of $47.06 and a one year high of $195.97.
A number of hedge funds have recently modified their holdings of SAGE. Bank of New York Mellon Corp boosted its holdings in SAGE Therapeutics by 36.5% during the 3rd quarter. Bank of New York Mellon Corp now owns 2,710,027 shares of the biopharmaceutical company’s stock valued at $168,834,000 after acquiring an additional 724,494 shares during the period. BlackRock Inc. boosted its holdings in SAGE Therapeutics by 16.4% during the 4th quarter. BlackRock Inc. now owns 3,444,171 shares of the biopharmaceutical company’s stock valued at $567,290,000 after acquiring an additional 486,135 shares during the period. Carillon Tower Advisers Inc. purchased a new stake in SAGE Therapeutics during the 4th quarter valued at about $74,300,000. New York State Common Retirement Fund boosted its holdings in SAGE Therapeutics by 258.0% during the 3rd quarter. New York State Common Retirement Fund now owns 149,564 shares of the biopharmaceutical company’s stock valued at $9,318,000 after acquiring an additional 107,782 shares during the period. Finally, Emerald Advisers Inc. PA boosted its holdings in SAGE Therapeutics by 123.0% during the 4th quarter. Emerald Advisers Inc. PA now owns 168,785 shares of the biopharmaceutical company’s stock valued at $27,801,000 after acquiring an additional 93,106 shares during the period. Institutional investors own 95.47% of the company’s stock.
WARNING: This report was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.americanbankingnews.com/2018/02/13/sage-therapeutics-inc-sage-receives-consensus-recommendation-of-buy-from-brokerages.html.
SAGE Therapeutics Company Profile
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.